Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Uptravi Generic Name & Formulations
Legal Class
Rx
General Description
Selexipag 200mcg, 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg; tabs.
Pharmacological Class
Prostacyclin receptor agonist.
See Also
How Supplied
Tabs 200mcg—60, 140; 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg—60; Titration pack—1 (140 x 200mcg tabs) + (60 x 800mcg tabs); Single-dose vial (10mL)—1
Manufacturer
Generic Availability
NO
Uptravi Indications
Indications
Pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional Class II–III symptoms, to delay disease progression and reduce the risk of hospitalization for PAH.
Uptravi Dosage and Administration
Adult
Swallow whole; may take with food to improve tolerability. Initially 200mcg twice daily; increase by 200mcg increments twice daily at weekly intervals to highest tolerated dose up to 1600mcg twice daily; reduce to previous dose if not tolerated. Moderate hepatic impairment (Child-Pugh class B): initially 200mcg once daily; increase in 200mcg increments once daily at weekly intervals as tolerated. Concomitant moderate CYP2C8 inhibitors: reduce Uptravi dose to once daily.
Children
Not established.
Uptravi Contraindications
Contraindications
Concomitant strong CYP2C8 inhibitors (eg, gemfibrozil).
Uptravi Boxed Warnings
Not Applicable
Uptravi Warnings/Precautions
Warnings/Precautions
Discontinue if pulmonary veno-occlusive disease confirmed. Severe hepatic impairment (Child-Pugh class C): avoid. Pregnancy. Nursing mothers: not recommended.
Uptravi Pharmacokinetics
See Literature
Uptravi Interactions
Interactions
See Contraindications. Potentiated by moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox, teriflunomide); reduce dosing (see Adults). Antagonized by CYP2C8 and UGT 1A3 or 2B7 inducers (eg, rifampin); increase up to twice the dose.
Uptravi Adverse Reactions
Adverse Reactions
Headache, diarrhea, nausea, jaw pain, vomiting, pain in extremity, myalgia, flushing, arthralgia, rash, anemia, decreased appetite.
Uptravi Clinical Trials
See Literature
Uptravi Note
Not Applicable
Uptravi Patient Counseling
See Literature
